TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
Year: 2021
Type: article
Study design: Observational Study
Abstract: cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known as PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have limited clinical efficacy in patients with AML. Natural killer (NK) cells are central players in AML-targeting immune responses. However, little is known on the relationship between co-inhibitory receptors expressed by NK cells and the ability of the latter to control AML. Here, we show that hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3) is highly expressed by NK cells from AML patients, correlating with improved functional licensing and superior effector functions. Altogether, our data indicate that NK cell frequency as well as TIM-3 expression levels constitute prognostically relevant biomarkers of active immunity against AML.
Source: OncoImmunology
Institutions: Sotio (Czechia), Charles University, University Hospital in Motol, Institute of Haematology and Blood Transfusion, Czech Academy of Sciences, Czech Academy of Sciences, Institute of Microbiology, University Hospital Plzen, University of Chicago, Université Paris Cité, Yale University, Weill Cornell Medicine
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,913
OpenAlex ID: W3133854897